The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian cancer, according to data from an ongoing Phase 1/2 trial. Findings from the trial, called ARTISTRY-1 (NCT02799095), also showed the combination therapy had a manageable safety and tolerability profile. Given these results, Alkermes, the developer of ALKS 4230, is now planning to launch a prospective study…
You must be logged in to read/download the full post.
The post ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression appeared first on BioNewsFeeds.